52U.F Stock Analysis
52
Uncovered
Hyloris Pharmaceuticals SA is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege. The company went IPO on 2020-06-29. The firm focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. The company has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. The company also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.